Back to search

Article

Revisiting Tumor Mutational Burden Cutoff: Multi-Study Replicability in Immunotherapy

2025-01-03

Abstract excerpt

<h4>PURPOSE</h4> Tumor Mutational Burden (TMB) is a crucial biomarker for predicting the effectiveness of cancer immunotherapy. However, ongoing debates about the optimal cutoff significantly impact the clinical application of immunotherapy. The purpose of our study is to comprehensively evaluate TMB cutoffs for predicting immunotherapy outcomes across multiple studies, considering both cancer type and outcome en...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
eab0c379-e77a-55e8-95c4-60ba672b9b7e
DOI
10.1101/2025.01.02.631104
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Revisiting Tumor Mutational Burden Cutoff: Multi-Study Replicability in ImmunotherapyDOI 10.1101/2025.01.02.631104
Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.Semantic proximity
A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours.Semantic proximity
A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid TumoursSemantic proximity
Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.Semantic proximity
Clinical significance of tumour mutation burden in immunotherapy across multiple cancer types: an individual meta-analysis.Semantic proximity
Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.Semantic proximity
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Semantic proximity
Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachSemantic proximity
Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.Semantic proximity
Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.Semantic proximity
Tissue and Blood-Based Tumor Mutational Burden Predicts Treatment Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.Semantic proximity
The Predictive efficacy of tumor mutational burden for immune Checkpoint Inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trialsSemantic proximity
Select a neighboring publication to make it the new centre.